This transcript has been edited for clarity. Vallerie McLaughlin, MD: Hello, and welcome to this podcast series. I'm Dr Vallerie McLaughlin, the Kim A. Eagle Endowed Professor of Cardiovascular ...

Researchers describe the underlying signaling pathway that results in pulmonary arterial hypertension and a novel monoclonal antibody therapy that blocks the abnormal blood vessel formation ...

Overall Count and Share for 'Unit Pulmonary Hypertension: Pathophysiology and Novel Therapies' based on the 12-month time frame mentioned above. Note: Articles may be assigned to more than one subject ...

Although some cases of PAH have known causes, such as genetic factors, many cases have no identifiable underlying cause and are designated as idiopathic. Early diagnosis and treatment are critical for ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

Pulmonary arterial hypertension is a rare form of pulmonary hypertension that poses diagnostic challenges and often comes with a delayed diagnosis. Pulmonary hypertension (PH) is organized into 5 ...

Q: I am an 85-year-old woman, and I’ve been incredibly healthy all my life, until a couple of years ago. Recently, my complaints of breathlessness and fatigue took me to a pulmonologist, who diagnosed ...

What is persistent pulmonary hypertension of the newborn? In short, PPHN is a serious breathing problem that affects very young babies. It usually affects babies born at full term or at 34 weeks or ...

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.